Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Report Date: March 30, 2023
Reporting Period: Fourth quarter and fiscal year ended December 31, 2022
Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the specified period. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are detailed in the provided text. The document solely references the announcement of results for the fourth quarter and fiscal year 2022 without quantifying changes versus prior periods.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information in the report (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 30, 2023) for actual revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and any associated accounting election impacts.
- Confirm the specific details of the fourth quarter and full-year 2022 operational results not present in this summary.
- Check for any subsequent filings that may incorporate the press release by reference.